Association of endostatin with mortality in patients with chronic heart failure

European Journal of Clinical Investigation

Volumn 44, Issue 2, 2014, Pages 125-135

  Gouya, Ghazaleh ^a   Siller Matula, Jolanta M ^a   Fritzer Szekeres, Monika ^a   Neuhold, Stephanie ^a   Storka, Angela ^a   Neuhofer, Lisa M ^a   Clodi, Martin ^a   Hülsmann, Martin ^a   Pacher, Richard ^a   Wolzt, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

All cause mortality; Endostatin; Heart failure

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALLOPURINOL; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; COHORT ANALYSIS; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HEART FAILURE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL MORTALITY; PATIENT IDENTIFICATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; CHRONIC DISEASE; EPIDEMIOLOGY; HOSPITALIZATION; METABOLISM; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; CHRONIC DISEASE; ENDOSTATINS; EPIDEMIOLOGIC METHODS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; YOUNG ADULT;

EID: 84892476215     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12197     Document Type: Article

References (39)

1. McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005;365:1877-89.
2. Zachariah JP, Colan SD, Lang P, Triedman JK, Alexander ME, Walsh EP et al. Circulating matrix metalloproteinases in adolescents with hypertrophic cardiomyopathy and ventricular arrhythmia. Circ Heart Fail 2012;5:462-6.
3. Malmqvist K, Ohman KP, Lind L, Nystrom F, Kahan T. Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin. J Intern Med 2002;252:430-9.
4. Tomanek RJ. Response of the coronary vasculature to myocardial hypertrophy. J Am Coll Cardiol 1990;15:528-33.
5. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005;115:2108-18.
6. Ohtsuka T, Inoue K, Hara Y, Morioka N, Ohshima K, Suzuki J et al. Serum markers of angiogenesis and myocardial ultrasonic tissue characterization in patients with dilated cardiomyopathy. Eur J Heart Fail 2005;7:689-95.
7. Patel JV, Abraheem A, Chackathayil J, Gunning M, Creamer J, Hughes EA et al. Circulating biomarkers of angiogenesis as indicators of left ventricular systolic dysfunction amongst patients with coronary artery disease. J Intern Med 2009;265:562-7.
8. Friehs I, Margossian RE, Moran AM, Cao-Danh H, Moses MA, del Nido PJ. Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis. Basic Res Cardiol 2006;101:204-13.
9. Wu B, Zhang Z, Lui W, Chen X, Wang Y, Chamberlain AA et al. Endocardial cells form the coronary arteries by angiogenesis through myocardial-endocardial VEGF signaling. Cell 2012;151:1083-96.
10. Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13:649-63.
11. Feldman AL, Pak H, Yang JC, Alexander HR Jr, Libutti SK. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer 2001;91:1525-9.
12. Feldman AL, Alexander HR Jr, Yang JC, Linehan WM, Eyler RA, Miller MS et al. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 2002;95:1637-43.
13. Suzuki M, Iizasa T, Ko E, Baba M, Saitoh Y, Shibuya K et al. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 2002;35:29-34.
14. Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999;274:11721-6.
15. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999;99:1726-32.
16. Mitsuma W, Kodama M, Hanawa H, Ito M, Ramadan MM, Hirono S et al. Serum endostatin in the coronary circulation of patients with coronary heart disease and its relation to coronary collateral formation. Am J Cardiol 2007;99:494-8.
17. Panchal VR, Rehman J, Nguyen AT, Brown JW, Turrentine MW, Mahomed Y et al. Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease. J Am Coll Cardiol 2004;43:1383-7.
18. Givvimani S, Tyagi N, Sen U, Mishra PK, Qipshidze N, Munjal C et al. MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch Physiol Biochem 2010;116:63-72.
19. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
20. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
21. Osranek M, Seward JB, Buschenreithner B, Bergler-Klein J, Heger M, Klaar U et al. Diastolic function assessment in clinical practice: the value of 2-dimensional echocardiography. Am Heart J 2007;154:130-6.
22. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
23. Vila G, Grimm G, Resl M, Heinisch B, Einwallner E, Esterbauer H et al. B-type natriuretic peptide modulates ghrelin, hunger, and satiety in healthy men. Diabetes 2012;61:2592-6.
24. van der Zander K, Houben AJ, Hofstra L, Kroon AA, de Leeuw PW. Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study. Am J Physiol Heart Circ Physiol 2003;285:H1206-12.
25. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-83.
26. Lainchbury JG, Richards AM, Nicholls MG, Espiner EA, Yandle TG. Brain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment. J Clin Endocrinol Metab 1999;84:723-9.
27. Nikolova A, Ablasser K, Wyler von Ballmoos MC, Poutias D, Kaza E, McGowan FX et al. Endogenous angiogenesis inhibitors prevent adaptive capillary growth in left ventricular pressure overload hypertrophy. Ann Thorac Surg 2012;94:1509-17.
28. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-72.
29. Peterson JT, Li H, Dillon L, Bryant JW. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 2000;46:307-15.
30. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest 2005;115:599-609.
31. Fertin M, Lemesle G, Turkieh A, Beseme O, Chwastyniak M, Amouyel P et al. Serum MMP-8: a novel indicator of left ventricular remodeling and cardiac outcome in patients after acute myocardial infarction. PLoS One 2013;8:e71280.
32. Heljasvaara R, Nyberg P, Luostarinen J, Parikka M, Heikkila P, Rehn M et al. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp Cell Res 2005;307:292-304.
33. Isobe K, Kuba K, Maejima Y, Suzuki J, Kubota S, Isobe M. Inhibition of endostatin/collagen XVIII deteriorates left ventricular remodeling and heart failure in rat myocardial infarction model. Circ J 2010;74:109-19.
34. Mehrabi MR, Serbecic N, Tamaddon F, Kaun C, Huber K, Pacher R et al. Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease. Cardiovasc Res 2002;56:214-24.
35. Uemura R, Xu M, Ahmad N, Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 2006;98:1414-21.
36. Ahmed A, Husain A, Love TE, Gambassi G, Dell'Italia LJ, Francis GS et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006;27:1431-9.
37. Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O'Connor CM, Califf RM et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007;9:1064-9.
38. Lopez B, Querejeta R, Gonzalez A, Sanchez E, Larman M, Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004;43:2028-35.
39. Neuhold S, Huelsmann M, Pernicka E, Graf A, Bonderman D, Adlbrecht C et al. Impact of tricuspid regurgitation on survival in patients with chronic heart failure: unexpected findings of a long-term observational study. Eur Heart J 2013;34:844-52.